These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 35451891)

  • 1. Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?
    Zardavas D
    Expert Opin Investig Drugs; 2022 Jun; 31(6):633-644. PubMed ID: 35451891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
    Weiss J; Glode A; Messersmith WA; Diamond J
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
    [No Abstract]   [Full Text] [Related]  

  • 3. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan.
    Schreiber AR; Andress M; Diamond JR
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1303-1311. PubMed ID: 34651524
    [No Abstract]   [Full Text] [Related]  

  • 4. Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan.
    McGuinness JE; Kalinsky K
    Expert Opin Biol Ther; 2021 Jul; 21(7):903-913. PubMed ID: 33089726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Drug Conjugates in Triple Negative Breast Cancer.
    Keskinkilic M; Sacks R
    Clin Breast Cancer; 2024 Apr; 24(3):163-174. PubMed ID: 38341370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles.
    Fenton MA; Tarantino P; Graff SL
    Curr Oncol; 2023 Nov; 30(12):10211-10223. PubMed ID: 38132377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.
    Shastry M; Jacob S; Rugo HS; Hamilton E
    Breast; 2022 Dec; 66():169-177. PubMed ID: 36302269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unveiling the antibody-drug conjugates portfolio in battling Triple-negative breast cancer: Therapeutic trends and Future horizon.
    Khadela A; Soni S; Shah AC; Pandya AJ; Megha K; Kothari N; Cb A
    Med Oncol; 2022 Dec; 40(1):25. PubMed ID: 36456774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
    Adams E; Wildiers H; Neven P; Punie K
    ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.
    Schreiber AR; O'Bryant CL; Kabos P; Diamond JR
    Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs).
    Dri A; Arpino G; Bianchini G; Curigliano G; Danesi R; De Laurentiis M; Del Mastro L; Fabi A; Generali D; Gennari A; Guarneri V; Santini D; Simoncini E; Zamagni C; Puglisi F
    Cancer Treat Rev; 2024 Feb; 123():102672. PubMed ID: 38118302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?
    Zangardi ML; Spring LM; Nagayama A; Bardia A
    Expert Opin Investig Drugs; 2019 Feb; 28(2):107-112. PubMed ID: 30507322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
    Furlanetto J; Marmé F; Loibl S
    Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
    Nagayama A; Vidula N; Bardia A
    Oncology (Williston Park); 2021 May; 35(5):249-254. PubMed ID: 33983696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-Drug Conjugates: A New Therapeutic Approach for Triple-Negative Breast Cancer.
    Al Jarroudi O; El Bairi K; Curigliano G; Afqir S
    Cancer Treat Res; 2023; 188():1-27. PubMed ID: 38175340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer.
    Cortesi M; Zanoni M; Maltoni R; Ravaioli S; Tumedei MM; Pirini F; Bravaccini S
    Expert Opin Ther Targets; 2022 Jul; 26(7):593-602. PubMed ID: 35962580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the therapeutic potential of ADC combination for triple-negative breast cancer.
    Lu L; Niu Z; Chao Z; Fu C; Chen K; Shi Y
    Cell Mol Life Sci; 2023 Nov; 80(12):350. PubMed ID: 37930428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
    Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
    Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
    O'Shaughnessy J; Brufsky A; Rugo HS; Tolaney SM; Punie K; Sardesai S; Hamilton E; Loirat D; Traina T; Leon-Ferre R; Hurvitz SA; Kalinsky K; Bardia A; Henry S; Mayer I; Zhu Y; Phan S; Cortés J
    Breast Cancer Res Treat; 2022 Sep; 195(2):127-139. PubMed ID: 35545724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.